Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: A systematic review

Critical Reviews in Oncology/Hematology

Volumn 85, Issue 1, 2013, Pages 21-31

  Schlaak, M ^a   Theurich, S ^a   Pickenhain, J ^a   Skoetz, N ^a   Kurschat, P ^a   von Bergwelt Baildon, M ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Allogeneic hematopoetic stem cell transplantation; Bone marrow transplantation; Meta analysis; Mycosis fungoides; Primary cutaneous T cell lymphoma; Sezary syndrome; Systematic review

Indexed keywords

ADVANCED PRIMARY CUTANEOUS T CELL LYMPHOMA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER REGRESSION; CUTANEOUS T CELL LYMPHOMA; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANIMALS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84870775837     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.06.002     Document Type: Review

References (42)

1. Whittaker S.J., Foss F.M. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treatment Reviews 2007, 33(2):146-160.
2. Kim Y.H., Liu H.L., Mraz-Gernhard S., Varghese A., Hoppe R.T. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Archives of Dermatology 2003, 139(7):857-866.
3. Stang A., Streller B., Katalinic A., et al. Incidence of skin lymphoma in Germany. Annals of Epidemiology 2006, 16(3):214-222.
4. Vidulich K.A., Talpur R., Bassett R.L., Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. International Journal of Dermatology 2009, 48(3):243-252.
5. Saunes M., Nilsen T.I., Johannesen T.B. Incidence of primary cutaneous T-cell lymphoma in Norway. British Journal of Dermatology 2009, 160(2):376-379.
6. Stadler R., Assaf C., Klemke C.D., et al. Short German guidelines: cutaneous lymphomas. Journal der Deutschen Dermatologischen Gesellschaft 2008, 6(Suppl. 1):S25-S31.
7. Whittaker S.J., Marsden J.R., Spittle M., Russell Jones R. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. British Journal of Dermatology 2003, 149(6):1095-1107.
8. Duarte R.F., Schmitz N., Servitje O., Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplantation 2008, 41(7):597-604.
9. Dearden C. Is there a role for hemopoietic stem-cell transplantation in CTCL?. Oncology 2007, 21(2 (Suppl. 1)):24-28.
10. Duarte R.F., Canals C., Onida F., et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2010, 28(29):4492-4499.
11. Duvic M., Donato M., Dabaja B., et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2010, 28(14):2365-2372.
12. Introcaso C.E., Leber B., Greene K., Ubriani R., Rook A.H., Kim E.J. Stem cell transplantation in advanced cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology 2008, 58(4):645-649.
13. Molina A., Zain J., Arber D.A., et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2005, 23(25):6163-6171.
14. Wu P.A., Kim Y.H., Lavori P.W., Hoppe R.T., Stockerl-Goldstein K.E. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 2009, 15(8):982-990.
15. Foss F.M., Ihde D.C., Breneman D.L., et al. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1992, 10(12):1907-1913.
16. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001, 97(3):631-637.
17. Wheatley K., Gray R. Commentary: Mendelian randomization - an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. International Journal of Epidemiology 2004, 33(1):15-17.
18. Lefebvre C.M.E., Glanville J. Chapter 6: searching for studies. Cochrane handbook for systematic reviews of interventions version 5.0.0 (updated February 2008) 2008, The Cochrane Collaboration. J.P.T. Higgins, S. Green (Eds.).
19. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998, 17(24):2815-2834.
20. Tierney J.F.S.L., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
21. Deeks J.J.H.J., Altman D.G. Analysing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions version 5.0.0 (updated February 2008) 2008, The Cochrane Collaboration.
22. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997, 315(7109):629-634.
23. Lau J., Ioannidis J.P., Terrin N., Schmid C.H., Olkin I. The case of the misleading funnel plot. British Medical Journal 2006, 333(7568):597-600.
24. Sterne J.A.C.E.M., Moher D. Chapter 10: addressing reporting biases. Cochrane handbook for systematic reviews of interventions version 5.0.0 (updated September 2008) 2008, The Cochrane Collaboration. J. Higgins, S. Green (Eds.).
25. Schlaak M., Pickenhain J., Theurich S., Skoetz N., von Bergwelt-Baildon M., Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Systematic Review 2012, 1:CD008908.
26. Hoff N.P., Bruch-Gerharz D. The role of hematopoietic stem-cell transplantation in cutaneous T-cell lymphoma. Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia 2010, 145(3):345-359.
27. Apisarnthanarax N., Talpur R., Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. American Journal of Clinical Dermatology 2002, 3(3):193-215.
28. Knobler E. Current management strategies for cutaneous T-cell lymphoma. Clinics in Dermatology 2004, 22(3):197-208.
29. Horwitz S.M.O.E., Duvic M., Porcu P., Kim Y.H. Review of the treatment of mycosis fungoides and Sézary syndrome: a stage-based approach. Journal of the National Comprehensive Cancer Network 2008, 6(4):436-442. [PubMed: 18433609].
30. Dummer R., Whittaker S., Hasan B., et al. EORTC 21012: Phase II multicentre study of CaelyxTM monotherapy in patients with advanced mycosis fungoides stage IIb, Iva and IVb with or without previous chemotherapy. ASH Annual Meeting Abstracts 2010, 116(21). p. 2823-.
31. Koeppel M.C., Stoppa A.M., Resbeut M., et al. Mycosis fungoides and allogenic bone marrow transplantation. Acta dermato-venereologica 1994, 74(4):331-332.
32. Molina A., Nademanee A., Arber D.A., Forman S.J. Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 1999, 5(6):400-404.
33. Ringden O., Karlsson H., Olsson R., Omazic B., Uhlin M. The allogeneic graft-versus-cancer effect. British Journal of Haematology 2009, 147(5):614-633.
34. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005, 19(12):2304-2312.
35. Karanes C.N.G., Chitphakdithai P., Agura E., et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biology of Blood and Marrow Transplantation 2008, 14(9 (Suppl.)):8-15. [PubMed: 18721775].
36. Feinstein L., Storb R. Nonmyeloablative hematopoietic cell transplantation. Current Opinion in Oncology 2001, 13(2):95-100.
37. Ljungman P., Bregni M., Brune M., et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplantation 2010, 45(2):219-234.
38. Rocha V., Mohty M., Gluckmann E., Rio B. Reduced-intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies. Current Opinion in Oncology 2009, 21(Suppl. 1):S31-S34.
39. Storb R. Reduced-intensity conditioning transplantation in myeloid malignancies. Current Opinion in Oncology 2009, 21(Suppl. 1):S3-S5.
40. Kolb H.J. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sanguinis 1998, 74(Suppl. 2):321-329.
41. Roddie C., Peggs K.S. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opinion on Biological Therapy 2011, 11(4):473-487.
42. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112(12):4371-4383.